Name | (2R,3R,4R,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol |
---|---|
Synonyms |
MK-608
Lamevudine (2R,3R,4R,5R)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol 7-deaza-2’-C-methyladenosine 7-Deaza-2'-C-methyladenosine 7DMA 7-(2-C-Methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-(2-C-methyl-β-D-ribofuranosyl)- |
Description | MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay[1]. |
---|---|
Related Catalog | |
Target |
EC50: 0.3 μM (HCV replication)[1] |
In Vivo | Oral dosing of MK-0608 results in a potent antiviral effect. In preclinical pharmacokinetic experiments with rats, dogs, and rhesus monkeys, MK-0608 demonstrates good to excellent oral bioavailability (50 to 100%) and long plasma half-lives in dogs and rhesus macaques (9 and 14 h, respectively)[1]. Animal Model: The HCV-infected chimpanzees[1] Dosage: 1 mg/kg Administration: Administered orally; once daily for 37 days Result: Chimpanzee X6 had a baseline viral load that varied from 1,110 to 12,900 IU/mL, and chimpanzee X4 had a baseline viral load of 3×106 to 9×106 IU/mL. |
References |
Density | 1.8±0.1 g/cm3 |
---|---|
Boiling Point | 620.7±55.0 °C at 760 mmHg |
Melting Point | 222 °C(Solv: methanol (67-56-1) |
Molecular Formula | C12H16N4O4 |
Molecular Weight | 280.280 |
Flash Point | 329.2±31.5 °C |
Exact Mass | 280.117157 |
PSA | 126.65000 |
LogP | 0.22 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.769 |
Storage condition | 2-8°C |